Lowering the cost of cancer drugs signals a step towards equitable care

The government’s decision to reduce customs duties on a range of life-saving medicines, including key Cancer therapies and drugs for rare conditions, reflects a considered attempt to ease the financial burden on patients navigating long-term treatment. Coming into effect from April 1, the measure is expected to bring down prices of several critical formulations that have remained out of reach for many households.

In India, where a significant share of healthcare expenditure is borne out of pocket, the cost of treatment often determines the course of care itself. For patients with cancer and other chronic illnesses, this reality translates into delayed therapy, interrupted medication cycles, or, in some cases, complete withdrawal from treatment. By targeting duties on essential drugs, the government has sought to address one of the most immediate barriers to access.

The move also arrives at a time when the incidence of non-communicable diseases is rising steadily. As treatment protocols become more advanced, they also become more expensive, widening the gap between medical possibility and affordability. In such a scenario, fiscal interventions assume critical importance in bridging this divide.

However, the success of this step will depend on how effectively the benefits are transmitted to patients. Price reductions at the import stage do not always translate into proportional cuts at the retail level. Ensuring that hospitals, distributors, and pharmacies pass on these gains without distortion will be key to realising the policy’s intent.

There is also a broader structural question at play. While duty cuts provide immediate relief, long-term affordability will hinge on strengthening domestic manufacturing, encouraging generic competition, and improving procurement systems within public healthcare.

Even so, the present decision offers a measure of respite to patients and families who often confront not just illness, but the anxiety of mounting costs. It is a reminder that in healthcare policy, incremental steps can carry meaningful impact when they are directed at the points of greatest vulnerability.